Omalizumab
Xolair (omalizumab) is an antibody pharmaceutical. Omalizumab was first approved as Xolair on 2003-06-20. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma and urticaria. The pharmaceutical is active against Immunoglobulin heavy constant epsilon.
| Trade Name | Xolair |
|---|---|
| Common Name | Omalizumab |
| Indication | asthma, urticaria |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
